Potassium and the use of RAAS inhibitors in Heart Failure with reduced ejection fraction: data from BIOSTAT-CHF

Joost Beusekamp\* (1), Jasper Tromp\*, MD (1,2), Haye van der Wal (1), S.D. Anker, MD (3), J.G. Cleland, MD (4), K. Dickstein, MD, PhD (5,6), G. Filippatos, MD (7), P. van der Harst, MD, PhD (1), H.L. Hillege, PhD (1), C.C. Lang, MD (8), M. Metra, MD (9), L.L. Ng, MD (9), P. Ponikowski, MD (11), N.J Samani, MD (10), D.J. van Veldhuisen, MD, PhD (1), A. H Zwinderman, PhD (12), P. Rossignol, MD, PhD (13), F. Zannad, MD, PhD (13), Adriaan A. Voors, MD, PhD (1), and Peter van der Meer, MD, PhD (1).

\*These authors contributed equally.

1. Department of Cardiology, University of Groningen, Groningen, the Netherlands

2. National Heart Centre Singapore, Singapore

3. Innovative Clinical Trials, Department of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany

4. National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, United Kingdom.

5. University of Bergen, Bergen, Norway

6. Stavanger University Hospital, Stavanger, Norway

7. National and Kapodistrian University of Athens, School of Medicine & Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece

8. School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK

9. Institute of Cardiology, Department of medical and surgical specialties, radiological sciences and public health; University of Brescia, Italy

10. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, LE3 9QP, UK

11. Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, Wroclaw, Poland.

12. Department of Epidemiology, biostatistics & bioinformatics, Academic Medical Center, Amsterdam, The Netherlands Inserm CIC 1433,

13. Inserm CIC-P 1433, Université de Lorraine, CHRU de Nancy, FCRIN INI-CRCT, Nancy, France

**Correspondence to:** Peter van der Meer MD PhD, Department of Cardiology, Thorax Center, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, Groningen 9700 RB, The Netherlands; [p.van.der.meer@umcg.nl](mailto:p.van.der.meer@umcg.nl)

**Abstract**

**Background:** Hyperkalemia is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). Whether it affects the use of RAAS-inhibitors and thereby negatively impacts outcome is unknown. Therefore, we investigated the association between potassium and uptitration of ACE-inhibitor/ARB and its association with outcome.

**Methods and results:** Out of 2,516 patients from the BIOSTAT-CHF study, potassium levels were available in 1,666 patients with HFrEF. These patients were sub-optimally treated with ACEi/ARB or beta-blockers and were anticipated and encouraged to be uptitrated. Potassium levels were available at inclusion and 9 months. Outcome was a composite of all-cause mortality and HF-hospitalization at 2 years.

Patients were 67±12 years old and 77% was male. At baseline, median serum potassium was 4.2(3.9–4.6) mEq/L. After 9 months, 401 (24.1%) patients were successfully uptitrated with ACEi/ARB. During this period, mean serum potassium increased by 0.16±0.66 mEq/L (p<0.001). Baseline potassium was an independent predictor of lower ACEi/ARB dosage achieved (OR 0.70; 95%CI 0.51–0.98). An increase in potassium was not associated with adverse outcomes (HR 1.15; 95%CI 0.86–1.53). No interaction on outcome was found between baseline potassium, potassium increase during uptitration, or potassium at 9 months and increased dosage of ACEi/ARB (pinteraction >0.5 for all).

**Conclusion:** Higher potassium levels are an independent predictor of enduring lower dosages of ACEi/ARB. Higher potassium levels do not attenuate the beneficial effects of ACEi/ARB uptitration.

**Keywords:**

Hyperkalemia, guideline-directed medication, heart failure, RAASi, outcome

**List of abbreviations:**ACEi – Angiotensin-Converting Enzyme-Inhibitors

ARBs – Angiotensin Receptor Blockers

BNP – Brain Natriuretic Peptide

COPD – Chronic Obstructive Pulmonary Disease

CRP – C-Reactive Protein

eGFR – estimated Glomerular Filtration Rate

HF – Heart Failure

HFrEF – Heart Failure with reduced Ejection Fraction

LVEF – Left Ventricular Ejection Fraction

MRA – Mineralocorticoid Receptor Antagonist

NT-proBNP – N-terminal prohormone of Brain Natriuretic Peptide

RAASi – Renin Angiotensin Aldosterone System-Inhibitors

**Introduction**

Heart failure (HF) is associated with high mortality and morbidity (1). Current treatment possibilities for HF patients with a reduced ejection fraction (HFrEF) include ACE-inhibition (ACEi), angiotensin-receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA) and beta-blockers. These treatments have shown to improve outcomes for patients with HFrEF (2-5). Unfortunately, administration of recommended doses of guideline directed medication is not often achieved (6,7).

In the general population, hyperkalemia is common and may negatively impact administration of adequate dosages of ACEi and ARB (8). Unfortunately, knowledge on this association in patients with HF is absent. Additionally, hyperkalemia is associated with worse outcomes and potassium levels are therefore closely monitored during increase of the doses of inhibitors of the RAAS system in clinical trials (9-12). Both hyperkalemia as well as the effect of hyperkalemia on tolerating higher doses of RAAS inhibitors can severely impede outcomes and interfere with their survival benefit (8,13).

Currently, no data is available on the independent association of potassium levels (or potassium change during treatment) and the achieved dose of ACEi/ARB. Additionally, limited data is available on the interaction between ACEi/ARB and the association between hyperkalemia and clinical outcome in patients with HFrEF (14). Therefore, we studied the association between serum potassium levels and successful uptitration of ACEi/ARB to HF guideline-directed dosages in the BIOSTAT-CHF cohort, which was specially designed to study effects of uptitration (15). Furthermore, we studied the interaction between guideline-directed treatment and hyperkalemia on outcomes.

**Methods**

**Study cohort**For the present study, data from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), an international, multicenter, prospective, observational study was investigated. Patients received ≤50% of target dosages of ACEi/ARBs and/or beta-blockers at time of inclusion and treating physicians anticipated and encouraged an increase of fraction target dose of ACEi/ARBs and/or beta-blockers to guideline directed levels. Patients were included as in- or outpatients. Potassium was measured at time of inclusion. The first 3 months after inclusion were considered as an active uptitration period, followed by a stabilization period of 6 months. Detailed description of the rationale, design, and implementation of the BIOSTAT-CHF study has been reported elsewhere (15).

For the current study, only HF patients with HFrEF (LVEF<40%) with available potassium levels at baseline were included. Out of 2,516 patients from the original study cohort, 697 patients with a preserved or unknown ejection fraction were excluded. Of the remaining 1,819 patients, serum potassium levels were measured in 1,666 patients. Potassium measurements at 9 months were available in 918 patients (*Supplementary figure 1*).

**Definitions and study endpoints**Potassium levels were classified according to clinical reference ranges, i.e. hypokalemia; <3.5 mEq/L, normokalemia; 3.5 - 5.0 mEq/L, and hyperkalemia; >5.0 mEq/L (16). We defined successful uptitration as an increase of beta-blockers and ACEi/ARB if patients obtained over 50% of the target dose at 9 months of follow-up and the administered dose at 9 months was greater than the dose administered at baseline according to the ESC-guidelines (17). Patients who died between baseline and 9 months (N=203) were excluded from this analysis (supplementary figure 1). Patients receiving equal guideline recommended target doses (i.e. >= 100%) at baseline and 9 months were classified as successfully uptitrated patients. Patients receiving ≤ 50% of the guideline-recommended dose were labeled not successfully uptitrated (*Supplementary figure 2*). In sensitivity analysis, we did not include baseline doses and only tested for administered doses of ACEi/ARBs and beta-blocker at three months (18). The primary endpoint for outcome analyses of this study was a combined endpoint of all-cause mortality and HF related hospitalizations at 2 years. HF related hospitalizations were determined by the enrolling investigator.

**Statistical analysis**  
For baseline characteristics, study results for continuous variables are presented as the mean (± standard deviation), medians (+ interquartile ranges) or numbers with percentages where appropriate. Baseline characteristics were stratified by serum potassium levels in hypokalemia (<3.5 mEq/L), normokalemia (3.5-5.0 mEq/L), and hyperkalemia (>5.0 mEq/L), respectively. An increase or decrease in potassium between baseline and 9 months was determined as more than a 0.1 mEq/L difference between baseline and 9 months. Intergroup differences between more than two groups were tested using the one-way analysis of variance (ANOVA); Kruskal-Wallis test or chi2-test where appropriate. Q-Q plots and histograms were used to visually test all variables for normality. Normality was tested using the Kolmogorov-Smirnov test, when necessary. For further analyses, skewed variables were log-transformed to achieve normal distribution.

Relationship of potassium levels with successful uptitration between baseline and 9 months was studied using logistic regression. In a stepwise manner, this was corrected for clinically relevant confounders of potassium, which age, sex, eGFR, systolic blood pressure, diabetes mellitus, and ACEi/ARB usage at 9 months (in case of beta-blocker uptitration) or beta-blocker usage at 9 months (in case of ACEi/ARB uptitration). Additionally, we corrected for uptitration models that best predicted successful uptitration rates in this cohort for beta-blockers and ACEi/ARB (18). For beta-blockers, these include age, country of inclusion, diastolic blood pressure, heart rate, and signs of pulmonary congestion. For ACEi/ARB these include sex, BMI, eGFR, alkaline phosphatase, and country of inclusion, as published previously (18).The association between potassium and outcome is depicted using Kaplan-Meier curves for potassium levels at baseline, potassium levels at 9 months and a change of potassium levels between baseline and 9 months. A difference in survival was tested using the log-rank test. To investigate the association with survival of potassium in multivariable analyses, Cox regression analyses were performed correcting for clinically relevant variables, these include age, sex, eGFR, hypertension, diabetes mellitus, and ACEi/ARB or beta-blocker use at 9 months. Interaction analyses were performed to investigate the interaction between successful uptitration and its association with outcome of potassium levels (as a continuous variable).

A two-sided p-value <0.05 was considered statistically significant and 95% CI were presented for all odds ratios. For statistical analyses, Stata MP13 (StataCorp. 2013. *Stata Statistical Software: Release 13*. College Station, TX: StataCorp LP.) was used.

**Results**

**Baseline characteristics**  
Out of a total of 1,666 patients, 114 patients (6.9%) had potassium levels below 3.5 mEq/L, 1,418 patients (85.1%) had normal potassium levels (i.e. 3.5 to 5.0 mEq/L), and 134 patients (8.0%) had hyperkalemia (above 5.0 mEq/L) at baseline (*table 1*). Only 34 (2%) patients had potassium levels above 5.5 mEq/L. In the overall population, mean age (± SD) was 67 ± 12 years of which 77% were male. Patients with hyperkalemia were more often men, had lower heart rates and less signs of pulmonary congestion and peripheral edema. Estimated GFR was significantly lower in patients with hyperkalemia and patients with high serum potassium were more often on MRA treatment.

A difference in prevalence of hyper- and hypokalemia across Europe is depicted in *figure 1A and 1B*. Hyperkalemia was particularly prevalent in Slovenia (19%), Poland (13%), Serbia (12%) and Greece (11%) (figure 1A). After correction for potential confounders (i.e. renal function, history of diabetes mellitus, history of hypertension, fraction target dose of ACEi/ARB, beta-blocker, and MRA and uptake of diuretics (yes/no) at baseline), rates of hyperkalemia were highest in Slovenia, followed by Poland, Serbia, and Greece (P <0.05 for all). Highest rates of hypokalemia were found in the Netherlands (P<0.05) (*supplementary table 1A and 1B*). Differences in listed characteristics between European countries are displayed in *supplementary table 2*.

During 9 months’ follow-up potassium levels increased (0.16 ± 0.66 mEq/L, p<0.001) and 523 (57%) of patients experienced an increase of potassium levels between baseline and 9 months, while 319 (35%) of patients had a decrease in potassium. At 9 months, 21 patients (2.3%) had potassium levels below 3.5 mEq/L, 786 patients (85.4%) had normal potassium levels (i.e. 3.5 to 5.0 mEq/L), and 113 patients (12.3%) were patients with hyperkalemia (above 5.0 mEq/L). Of patients with hypokalemia at baseline, 53.5% also had available data at 9 months. In case of normokalemia and hyperkalemia at baseline, this was 55.6% en 50.7% at 9 months respectively (*supplementary table 3*).

**Association of potassium and uptitration of guideline directed medication**  
After 9 months, uptitration of ACEi/ARB was successful in a total of 401 patients (24.1%). For beta-blockers, successful uptitration was seen in 278 (16.7%) patients (*supplementary figure 2*). Results of logistic regression analyses are shown in *figure 2 and supplementary figure 3*. Higher serum potassium at baseline was associated with lower odds of successful uptitration at 9 months in univariable analyses (OR 0.77; 95%CI 0.62–0.95; p=0.016; per increment of 1.0 mEq/L potassium). Also after correcting for clinically relevant confounders (i.e. age, sex, eGFR, systolic blood pressure, diabetes mellitus, and beta-blocker usage at 9 months), higher potassium levels at baseline showed a significant association with less successful uptitration (OR 0.80; 95%CI 0.64–0.99; p=0.043). When correcting for the previously published uptitration model, higher potassium levels at baseline were still associated with lower odds of successful uptitration (OR 0.70; 95%CI 0.51–0.98; p=0.035). After excluding patients already on ACEi/ARB target dose, potassium remained predictive for successful uptitration when correcting for both the uptitration model (OR 0.52; 95%CI 0.35–0.78; p=0.002) and model 3 (OR 0.66; 95%CI 0.50-0.87; p= 0.003). Further adjustment by MRA uptake at target dose (yes/no) did not change the association between baseline potassium levels and ACEi/ARB uptitration when correcting for the uptitration model (OR 0.54 95%CI 0.35–0.81; p=0.003) as well as for model 3 (OR 0.68; 95%CI 0.51-0.89; p= 0.006). No interaction was observed between potassium and renal function for successful uptitration (Pinteraction 0.988) suggesting that the association between hyperkalemia and uptitration is similar across the renal function spectrum. In sensitivity analysis, baseline serum potassium was univariable associated with uptitration success of ACEi/ARB (OR 0.81; 95%CI 0.67–0.98; p=0.031). However, this was attenuated after multivariable adjustment (p=0.086). As expected, no association was found between baseline potassium levels and uptitration of beta-blockers. Higher serum potassium levels at 9 months were not associated with successful uptitration of ACEi/ARB or beta-blockers (*supplementary figure 3*). A potassium increase over 9 months was associated with successful uptitration of ACEi/ARB (OR 1.37; 95%CI 1.09-1.72; p= 0.008), but not of beta-blockers.

**Potassium and outcome**  
Results of survival analyses are presented in *figure 3a/b*, *supplementary figure 4,* and *Table 2.* Overall, 627 (37.6%) patients reached the combined endpoint at 2 years. Hypo- and hyperkalemia at baseline or potassium analyzed on a continuous scale were not associated with worse outcomes (*Table 2*). Similarly, a change between potassium levels at baseline and 9 months or potassium levels at 9 months were not significantly related to outcome. When used as a continuous variable, potassium change during 9 months was not associated with outcome (HR 0.98; 95%CI 0.81-1.19; p=0.844). Potassium levels at baseline, a change of potassium during uptitration or potassium levels after uptitration, did not attenuate the beneficial effects of successful uptitration of ACEi/ARBs or beta-blockers (Pinteraction >0.5 for all).

**Discussion**

This study shows that low and high serum potassium levels are common among patients with HFrEF. Potassium levels above 5.0 mEq/L were observed in 8% of HFrEF patients across Europe and being particularly prevalent in Eastern Europe and Greece. Furthermore, higher baseline potassium levels were an independent predictor of unsuccessful uptitration of ACEi/ARBs in HFrEF patients. Potassium levels or changes in potassium levels during uptitration were not associated with worse outcomes. Furthermore, a potassium increase during uptitration did not attenuate the beneficial effects of uptitration of ACEi/ARBs. The findings of this study might have implications for clinical practice, suggesting that lowering potassium levels in patients with hyperkalemia might lead to improved guideline directed treatment with ACEi and ARB. These data are important considering the availability of new potassium lowering drugs (19,20).

Our study shows an overall rate of baseline potassium abnormalities of 6.9% and 8.0% for hypo- and hyperkalemia respectively. Our results show a difference in prevalence of potassium abnormalities between European countries, even after rigorous multivariable correction, which might reflect differences in health systems or local practice (18). Our findings are in line with earlier reports from the Patients Hospitalized with acute heart failure and Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion (PROTECT) trial (6% and 9% respectively) and 6.7% and 3.3% in the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) trial (14). Overall, potassium levels increased during uptitration of ACEi/ARB, with 2.3% of patients having hypokalemia and 12.3% of patients having hyperkalemia at 9 months. During 9 months of follow-up, a significant increase of potassium was seen in the majority of patients (57.4%) and can be explained by the actively increased doses of ACEi and ARB. Unfortunately, the study design did not allow for analysis on early changes (e.g. <1 month) after dose adjustments.

In this study, higher potassium levels at baseline were associated with less uptitration of ACEi/ARB. This suggests that HF patients with hyperkalemia at the start of therapy are at greater risk for lower doses or discontinuation of ACEi/ARB, which impede outcomes (6,18). This is in line with earlier reports from a general patient population where high potassium levels were found to be responsible for a significant proportion of discontinuation or lowering of dosage of ACEi and ARB. Here, discontinuation or lowering of dosages of ACEi/ARB were associated with more adverse outcomes (8). Also in previous results from the BIOSTAT-CHF study, sub-optimal dosages of ACEi/ARB were associated with worse outcomes in HF patients (18). This suggests that lower dosages and/or discontinuation of ACEi/ARB due to high potassium levels severely impede outcomes.

Hypokalemia at baseline or at 9 months was not associated with worse outcomes. This is in line with earlier reports from the COACH, PROTECT and EVEREST trials, where potassium also did not show an independent association with outcome (14,21). Nevertheless, reports on the association of potassium with outcome are mixed. Previous results of post-hoc analyses performed in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial showed that hypokalemia (<4.0 mEq/L) is associated with adverse outcomes and amplified the beneficial effect of eplerenone (22,23). Additionally, a propensity matched study from Ahmed et al. showed that hypokalemia is associated with more adverse outcomes (22). In another sub-analysis of the Digitalis Investigation Group trial, Bowling et al. shows that this was also true for HF patients with CKD and that potassium also predicts a combined endpoint of all-cause mortality and HF rehospitalizations (24). However, it has been suggested that the association of hypokalemia with adverse outcomes reflect lower usage of MRA or higher diuretic usage and dosage, on which data was often not available in previous reports (22,24-26).

Regardless of its association with outcome, potassium levels did not attenuate the beneficial effects of ACEi/ARB and beta-blockers. Previously, results from the Randomized Aldactone Evaluation Study (RALES) showed that hyperkalemia was associated with higher mortality rates, but did not interfere with the beneficial effects of spironolactone (9). The EMPHASIS-HF trial showed that the favorable effects of eplerenone on outcome did not differ for hyperkalemic compared to normokalemic patients (25). Additionally, a sub-analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) trial showed that potassium levels also did not interfere with the beneficial effects of Candesartan (27). The findings of the current study confirm results of the post-hoc analysis of the CHARM trial, but also show that potassium levels do not interfere with the beneficial effects of ACEi/ARB uptitration. Previously, Lund et al. discussed the association between ACEi/ARB usage and renal function, indicating that even in HF patients with severe renal insufficiency, administering ACEi/ARB improves outcome (28,29). Nevertheless, it should be noted that potassium levels as well as increases of potassium levels during uptitration took place within the relative “normal” range of potassium levels of 3.0 mEq/L and 5.5 mEq/L. Additionally, our study shows for the first time that potassium increases during uptitration of ACEi and ARBs do not interfere with the beneficial effects of these lifesaving therapies.

**Study limitations**

This is a post-hoc analysis, which comes with the usual limitations of selection bias. Potassium levels were only measured twice, at baseline and at 9 months of follow-up. A non-repetitive measurement could falsely positive diagnose a HF patient with hyperkalemia. Repeated measurements could correct for this deviation, but were not available. Unfortunately, potassium levels were not monitored after the first 3 months of active uptitration. This would provide additional data on potassium fluctuations over time. Additionally, patients with no potassium measurement at 9 months could have died, suggesting caution in interpreting data on potassium and outcome at 9 months. Furthermore, we did not have any information about potassium supplementation as well as on diuretic dosages, which might interfere with potassium levels.

**Conclusion**

Potassium abnormalities are prevalent among HF patients. Higher potassium levels are associated with lower rates of successful ACEi/ARB uptitration. Potassium abnormalities are not related to adverse outcomes and do not attenuate the beneficial effects of successful ACEi/ARB uptitration.

**Disclosures**

Anker reports consultancy for Thermo Fisher, and Consultancy and Research Support from Vifor Pharma and Metra reports Consulting honoraria from Amgen, Bayer, Novartis, Servier. Other authors none declared. Rossignol: Personal fees (consulting) from Bayer, Novartis, Relypsa, AstraZeneca, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, and CTMA; lecture fees from CVRx; cofounder CardioRenal

**Acknowledgements**

BIOSTAT-CHF was funded by the European Commission [FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29].

**References**

(1) Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013 Jul;15(7):808-817.

(2) Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995 May 10;273(18):1450-1456.

(3) Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000 Mar 8;283(10):1295-1302.

(4) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011 Jan 6;364(1):11-21.

(5) Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 Jul 20;355(3):251-259.

(6) Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L, Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013 Oct;15(10):1173-1184.

(7) Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007 Sep;93(9):1137-1146.

(8) Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015 Sep;21(11 Suppl):S212-20.

(9) Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD, Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014 Jul;7(4):573-579.

(10) Luo J, Brunelli SM, Jensen DE, Yang A. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol 2016 Jan 7;11(1):90-100.

(11) Poggio R, Grancelli HO, Miriuka SG. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Postgrad Med J 2010 Mar;86(1013):136-142.

(12) Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA 2015 Nov 10;314(18):1973-1975.

(13) Egiziano G, Pilote L, Behlouli H, Daskalopoulou SS. Improved outcomes in heart failure treated with high-dose ACE inhibitors and ARBs: a population-based study. Arch Intern Med 2012 Sep 10;172(16):1263-1265.

(14) Tromp J, Ter Maaten JM, Damman K, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). Am J Cardiol 2017 Jan 15;119(2):290-296.

(15) Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016 Jun;18(6):716-726.

(16) Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004 Jan 21;43(2):155-161.

(17) Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016 Aug;18(8):891-975.

(18) Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017 Mar 11.

(19) Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015 Oct;17(10):1057-1065.

(20) Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015 May 23.

(21) Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M, EVEREST Trial Investigators. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Am J Cardiol 2015 Mar 15;115(6):790-796.

(22) Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007 Jun;28(11):1334-1343.

(23) Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 2016 Nov 20.

(24) Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010 Mar;3(2):253-260.

(25) Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014 Jan;7(1):51-58.

(26) Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013 Oct 22;62(17):1585-1593.

(27) Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007 Nov 13;50(20):1959-1966.

(28) Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J 2015 Sep 7;36(34):2318-2326.

(29) Dickstein K. Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues. Eur Heart J 2015 Sep 7;36(34):2279-2280.

**Figure legends**

*Figure 1. Incidence levels of hyperkalemia (A) and hypokalemia (B) per country*

*Figure 2*. Odds Ratios (95% CI) for successful uptitration of ACEi/ARB depicted for baseline potassium (as continuous variable). Model 1: Corrected for age, sex, and eGFR. Model 2: Corrected model 1, systolic blood pressure, and diabetes mellitus. Model 3: Corrected for model 2 and beta-blocker usage at 9 months. Uptitration Model: Corrected for BIOSTAT-CHF uptitration model Sex, BMI, eGFR, alkaline phosphatase, and country of inclusion

*Figure 3.* Combined endpoint of all-cause mortality and HF-hospitalization rates stratified by serum potassium levels in mEq/L at baseline (A) and 9 months (B).

*Table 1.* Baseline characteristics

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables (proportions %)** | **Total cohort  (n=1,666)** | **Pot < 3.5  (n=114)** | **3.5 ≤ Pot ≤ 5.0  (n=1,418)** | **Pot > 5.0  (n=134)** | **p-value** | **Trend** |
| **Demographics** | | | | | | |
| **Potassium levels (mEq/L)** | 4.3 (3.9 – 4.6) | 3.2 (3.1 – 3.4) | 4.3 (4.0 – 4.5) | 5.4 (5.2 – 5.5) | NA | NA |
| **Age (years)** | 69 (60 – 76) | 69 (63 – 76) | 68 (59 – 77) | 70 (62 – 75) | 0.808 | 0.974 |
| **Men** | 1,275 (77) | 69 (61) | 1,101 (78) | 105 (78) | <0.001 | 0.002 |
| **BMI (kg/m2)** | 26.9 (24.1 – 30.4) | 26.7 (24.2 – 31.4) | 26.9 (24.0 – 30.4) | 27.0 (24.2 – 30.1) | 0.688 | 0.726 |
| **Heart rate (/min)** | 76 (68 – 90) | 80 (70 – 97) | 77 (67 – 90) | 75 (68 – 90) | 0.019 | 0.020 |
| **LVEF (%)** | 27 ± 7 | 27 ± 7 | 27 ± 7 | 28 ± 7 | 0.434 | 0.134 |
| **SBP (mmHg)** | 123 ± 21 | 126 ± 24 | 123 ± 21 | 124 ± 20 | 0.169 | 0.903 |
| **NYHA class III-IV** | 557 (38) | 30 (32) | 484 (39) | 43 (38) | 0.466 | 0.476 |
| **eGFR (mL/min/1.73 m2)**   * **eGFR < 45 mL/min** | 65.0 ± 24.1  347 (21) | 64.2 ± 24.4  23 (20) | 65.8 ± 24.0  280 (20) | 56.5 ± 23.7  44 (33) | <0.001  0.002 | 0.015  0.009 |
| **Signs & symptoms** | | | | | | |
| **Pulmonary congestion** | 854 (52) | 73 (64) | 712 (51) | 67 (51) | 0.035 | 0.057 |
| **Extent of peripheral edema\***   * **Not present** * **Above Knee** | 595 (44)  75 (5) | 21 (23)  8 (9) | 511 (44)  64 (6) | 63 (52)  3 (2) | <0.001  0.139 | <0.001  0.047 |
| **Medical history** | | | | | | |
| **Diabetes mellitus** | 529 (32) | 34 (30) | 447 (32) | 48 (36) | 0.534 | 0.297 |
| **Myocardial infarction** | 641 (38) | 37 (32) | 555 (39) | 49 (37) | 0.330 | 0.574 |
| **Atrial fibrillation** | 713 (43) | 49 (43) | 615 (43) | 49 (37) | 0.314 | 0.272 |
| **Hypertension** | 976 (59) | 71 (62) | 826 (58) | 79 (59) | 0.700 | 0.632 |
| **eGFR <60** | 747 (45) | 52 (46) | 614 (43) | 81 (61) | 0.001 | 0.012 |
| **COPD** | 288 (17) | 21 (18) | 237 (17) | 30 (22) | 0.238 | 0.352 |
| **Laboratory** | | | | | | |
| **Hemoglobin (g/dL)** | 13.4 ± 1.9 | 13.0 ± 1.8 | 13.4 ± 1.9 | 13.3 ± 1.8 | 0.069 | 0.232 |
| **Erythrocytes (10e12/L)** | 4.5 (4.1 – 4.9) | 4.4 (4.1 – 4.9) | 4.5 (4.1 – 4.9) | 4.6 (4.1 – 5.0) | 0.817 | 0.632 |
| **Platelets (10e9/L)** | 214 (173 – 258) | 209 (171 – 261) | 212 (173 – 257) | 228 (187 – 281) | 0.019 | 0.023 |
| **NT-proBNP (ng/L)^** | 4447 (2359 – 8824) | 4132 (2621 – 7839) | 4402 (2250 – 8522) | 5947 (3211 – 11124) | 0.068 | 0.155 |
| **CRP (mg/L)** | 12.9 (5.5 – 26.4) | 16.5 (8.2 – 30.4) | 12.9 (5.4 – 26.4) | 10.2 (4.5 – 19.1) | 0.002 | 0.001 |
| **Creatinine (µmol/L)** | 102 (84 – 127) | 99 (77 – 124) | 101 (83 – 126) | 115 (91 – 150) | <0.001 | <0.001 |
| **Iron (µmol/L)** | 8 (5 – 13) | 8 (5 – 13) | 8 (5 – 13) | 9 (6 – 13) | 0.080 | 0.028 |
| **Medication** | | | | | | |
| **ACE-I/ARB** | 1,229 (74) | 83 (73) | 1,046 (74) | 100 (75) | 0.949 | 0.746 |
| **Beta-blocker** | 1,390 (83) | 91 (80) | 1,190 (84) | 109 (81) | 0.419 | 0.822 |
| **MRA** | 920 (55) | 52 (46) | 783 (55) | 85 (63) | 0.019 | 0.005 |
| **Diuretics** | 1,665 (100) | 114 (100) | 1,417 (100) | 134 (100) | 0.916 | 0.975 |
| **Digoxin** | 302 (18) | 12 (11) | 271 (19) | 19 (14) | 0.034 | 0.578 |

Values are given as proportions, means (±SD) or medians (IQR)   
ACEi = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, BMI = Body Mass Index, BNP = Brain Natriuretic Peptide, COPD = Chronic Obstructive Pulmonary Disease, CRP = C-reactive protein, eGFR = estimated Glomerular Filtration Rate, LVEF = Left Ventricular Ejection Fraction, MRA = Mineralocorticoid Receptor Antagonists, NT-proBNP = N-Terminal prohormone of Brain Natriuretic Peptide, NYHA = New York Heart Association, SBP = Systolic Blood Pressure.  
\* Extent of peripheral edema was determined in 1,367 patients.  
^ Serum NT-proBNP levels were determined in 736 patients.

*Table 2.* Cox proportional hazard regression model for the analysis of event rates for the combined endpoint (all-cause mortality + HF-hospitalizations) in HF patients stratified by potassium levels on baseline, 9 months, and potassium change.

|  |  |  |  |
| --- | --- | --- | --- |
| (n of patients ; n of event) | **<3.5 mEq/ L** | **3.5-5.0 mEq /L** | **>5.0 mEq /L** |
| (114 ; 46) | (1,418 ; 530) | (134 ; 51) |
| **Baseline** | HR (CI), p |  | HR (CI), p |
| Univariable | 1.10 (0.83-1.47) 0.493 | ref | 1.01 (0.77-1.31) 0.968 |
| Model 1 | 1.11 (0.83-1.48) 0.493 | ref | 0.90 (0.69-1.18) 0.448 |
| Model 2 | 1.12 (0.84-1.50) 0.430 | ref | 0.88 (0.67-1.15) 0.353 |
| Model 3 | 1.13 (0.84-1.51) 0.419 | ref | 0.89 (0.68-1.17) 0.406 |
| **9 months** | (21 ; 12) | (786 ; 212) | (113 ; 43) |
| Univariable | 1.65 (0.61-4.48) 0.328 | ref | 1.34 (0.80-2.24) 0.270 |
| Model 1 | 1.85 (0.68-5.04) 0.231 | ref | 1.22 (0.72-2.05) 0.466 |
| Model 2 | 1.75 (0.63-4.81) 0.280 | ref | 1.19 (0.70-2.01) 0.518 |
| Model 3 | 1.97 (0.71-5.49) 0.193 | ref | 1.19 (0.70-2.01) 0.513 |
| **Change** | **Decrease** | **No change** | **Increase** |
| (319 ; 103) | (78 ; 17) | (523 ; 146) |
| Univariable | 1.26 (0.96-1.65) 0.101 | ref | 1.23 (0.93-1.64) 0.148 |
| Model 1 | 1.25 (0.95-1.65) 0.105 | ref | 1.17 (0.88-1.56) 0.275 |
| Model 2 | 1.27 (0.96-1.66) 0.091 | ref | 1.15 (0.87-1.54) 0.328 |
| Model 3 | 1.23 (0.94-1.62) 0.135 | ref | 1.15 (0.86-1.53) 0.341 |

Model 1: Corrected for age, sex, and eGFR  
Model 2: Corrected for age, sex, eGFR, systolic blood pressure, and diabetes mellitus  
Model 3: Corrected for the age, sex, eGFR, systolic blood pressure, and diabetes mellitus, ACEi/ARB usage at 9 months, or beta-blocker usage at 9 months

Figure 1



Figure 2



Figure 3

